Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

Stockholders' Equity Note [Abstract]

Schedule of share-based compensation, stock options, activity

	Shares Underlying Options			Weighted Average Exercise Price		Weighted average Remaining Contractual Life (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2017		-		$	-		-		-
Acquired in Reverse Merger		802,268			5.44		4.13		-
Granted		410,081			2.04		9.51		-
Forfeited		(271,067	)		1.94		-		-
Outstanding at September 30, 2018		941,282		$	5.50		4.91		-

Schedule of share-based compensation,

	Three Months ended September 30,				Nine Months ended September 30,
	2018		2017		2018		2017
Sales and marketing	$	382,812	$	144,154	$	982,816	$	342,000
Research and development		2,127		-		8,837		-
General and administrative		402,797		144,154		996,735		367,000
Total	$	787,736	$	288,308	$	1,988,388	$	709,000

Schedule of share-based payment award, stock options, valuation assumptions

Fair value of common stock	$1.82 - $2.21
Expected volatility	118.10% - 143.50%
Dividend yield	$0
Risk-free interest	2.85% - 3.00%
Expected life (years)	5.125 - 5.33

Schedule of common stock warrant activity

	Number of Warrants			Weighted Average Exercise Price
Outstanding, December 31, 2017		878,146		$	9.84
Acquired, H-1 warrants		304,466			4.84
Acquired, H-3 warrants		84,004			5.52
Granted, H-4 warrants		2,684,300			2.60
Granted, I warrants		439,070			2.30
Granted, J warrants		1,560,696			1.00
Exercised, H-4 warrants		(1,560,696	)		0.60
Retired, Merger warrants		(878,146	)		9.84
Outstanding, September 30, 2018		3,511,840		$	2.12